The FINANCIAL — Kyowa Pharmaceutical Industry Co., Ltd. and Astellas Pharma Inc. on February 27 announced that the companies have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan.
Astellas submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.
When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan, according to Astellas Pharma.
Discussion about this post